Status
Conditions
Treatments
About
● the investigators aims to study the impact of using drug coated balloon in coronary artery bifurcation lesions on the procedural success rate & short-term MACE.
Full description
Study Design:
A prospective study. Patients who met the inclusion criteria will be enrolled in our study will be subdivided into 2 groups :-
Group A: patient Who will undergo conventional provisional stenting using standard technique with plain balloon angioplasty Group B: patient Who will undergo provisional stenting using Drug coated balloon The patients will be randomly assigned for each group using a computer randomizing software application.
Both group with pass 3 stages: - Pre-procedural Interventional procedure Post -procedural Pre- procedural
History taking:
Age & sex. Family history. Smoking status. Medical history including hypertension (HTN), diabetes mellitus (DM), renal impairment, etc.
Previous history of coronary artery disease, myocardial infarctions (MI), revascularization procedures Medical treatment and any significant history of allergy Previous intervention history regarding (site, type, diameter and length of the stent , complications and TIMI flow ) if available
General &Physical examination:
with special emphasis on vital data, decubitus ,lung osculation and peripheral pulsation
Laboratory investigations:
Including kidney function, complete blood count, and High sensitive troponin in case of acute coronary syndrome Echocardiography will be done routinely for all patients with special emphasis on ejection fraction (to be assessed by modified Simpson's method), left ventricular dimensions, resting segmental wall motion abnormalities (RSWMAs).
Interventional procedure. Angiographic analysis. Serial coronary angiography will be performed at baseline (before and after intervention) and angiograms will be obtained in multiple views after intra-coronary nitrate if coronary spasm is suspected. coronary angiograms will be digitally recorded and analyzed by experienced personnel using a validated offline quantitative angiographic system and the following data will be collected: -
Bifurcation lesion distribution:
Left main artery bifurcation Left anterior descending artery/diagonal bifurcation Left circumflex artery/obtuse marginal bifurcation Right coronary artery/posterolateral branch
Medina classification the investigators will use Medina classification for coronary bifurcation lesion in which recording any narrowing more than 50% in each of the three arterial segments of the bifurcation in the following order: proximal main vessel (PMV). Distal main branch (DMV). Side branch (SB)
(1) is used to indicate the presence of a significant stenosis and (0) the absence of stenosis
Main vessel
Proximal reference diameter (mm) Distal reference diameter (mm) Mean reference diameter (mm) Minimal lumen diameter (mm) Percentage diameter stenosis (%)) Lesion length (mm) Angiographic restenosis (%)
Side branch
Reference diameter (mm) Minimal lumen diameter (mm) Percentage diameter stenosis (%) Lesion length (mm)
Type of drug-eluting stents Sirolimus-eluting stents Everolimus-eluting stents Zotrolimus-eluting stents Biolimus A9-eluting stent Number of stent/drug-eluting balloon used Stent/drug-eluting balloon size (mm) Stent/drug-eluting balloon length (mm) Maximum balloon size (mm) Maximum inflation pressure (atmosphere) other coronary lesions
Intervention
The following data will be recorded: -
Post-procedural Medications will be prescribed according to 2018 ESC myocardial revascularization guidelines.
Patients will be assessed for immediate outcomes:
lesion success attainment of >50% residual stenosis of the target lesion, as measured by quantitative coronary angiographic analysis procedure success attainment of a final lesion success and no major complication as :-
A. Perforation with or without tamponade B. vascular access complications C. myocardial infarction D. contrast-induced nephropathy E. urgent coronary artery bypass grafting F. urgent repeat PCI G. Death.
Patients be assessed and monitor for 24 hours after the procedure and in the outpatient clinic after 6 months.
Follow up clinically after 6 months for MACEs
Study end points. Primary end point target is 6-month follow-up for:-
MACEs (major adverse cardiac events) defined as :-
Improvement or recurrence of symptoms (chest pain and dyspnea) Symptomatic patients will undergo coronary angiography and those who has no symptoms with undergo functional assessment using either (High dose dobutamine echo or Myocardial perfusion imaging )
Secondary end points included:
lesion success procedure success
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Angiographical exclusion criteria as follows
Primary purpose
Allocation
Interventional model
Masking
50 participants in 2 patient groups
Loading...
Central trial contact
Yousef Amin, MD; Ahmed M Hassan, MSc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal